NEW YORK (AP) - A Senate report says GlaxoSmithKline knew of possible heart attack risks tied to Avandia, its diabetes drug, years before such evidence became public.
Senators Max Baucus and Chuck Grassley released the report, which follows a two-year inquiry, on Saturday. They are also asking the U.S. Food and Drug Administration why it allowed a clinical trial of Avandia to go on even after the agency estimated that the drug caused 83,000 heart attacks between 1999 and 2007.
Representatives for GlaxoSmithKline and the FDA did not immediately return calls for comment Saturday.
In 2007, the FDA ordered a warning to be included on Avandia's label warning that it might increase the risk of heart attacks. But the label also says data on the risks are inconclusive.